SCHEMBL6607152

SCHEMBL6607152

Nc1cc(-c2ccccc2)nn1CCOc1ccc2cc(Br)ccc2c1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.46
KMT2A Q03164 8/20 0.46
MEN1 O00255 7/20 0.46
STAT3 P40763 2/20 0.46
GALR3 O60755 1/20 0.46
GAA P10253 1/20 0.46
NPY1R P25929 1/20 0.46
NPY2R P49146 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.45
LMNA P02545 3/20 0.45
HTT P42858 1/20 0.45
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 2/20 0.41
RXFP1 Q9HBX9 2/20 0.40
PRNP P04156 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALOX12 P18054 1/20 0.38
PKM P14618 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6602671 0.86 RXFP1 (0.39) MAPTKMT2AMEN1GAASMN1; SMN2
SCHEMBL6602524 0.85 ADORA1 (0.40) MAPTKMT2AMEN1LMNAHTT
SCHEMBL6607900 0.84 RXFP1 (0.38) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL6803979 0.83 MAPT (0.37) MAPTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL6605026 0.83 RXFP1 (0.37) MAPTKMT2AMEN1STAT3GALR3
SCHEMBL6601377 0.83 RXFP1 (0.39) MAPTKMT2AMEN1STAT3GALR3
SCHEMBL6602237 0.81 MAPT (0.47) MAPTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL6805483 0.81 KMT2A (0.36) MAPTKMT2AMEN1STAT3GALR3
SCHEMBL6809974 0.80 MAPT (0.35) MAPTKMT2AMEN1GAALMNA
SCHEMBL6606995 0.78 KMT2A (0.37) MAPTKMT2AMEN1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 MAPT 3013/4885KMT2A 2911/4885MEN1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.